While ACSL4 overexpression may confer some advantages, it may not fully compensate for these environmental constraints, leading to the observed lack of significant tumor size differences in the PBS-treated ACSL4 overexpression group compared to controls. The gene discussed is ACSL4; the disease is neoplasm.